AAAAAA

   
Results: 1-25 | 26-27
Results: 1-25/27
ORAL 5-FLUOROURACIL (5-FU) PLUS ENILURACIL (776C85) IN PATIENTS WITH METASTATIC COLORECTAL-CANCER - A QUALITY-OF-LIFE (QOL) EVALUATION
Authors: SCHILSKY R BUKOWSKI R ROWINSKY E BURRIS H CRAWFORD J HOCHSTER H OROURKE M GLENDENNING A BARTON C
Citation: R. Schilsky et al., ORAL 5-FLUOROURACIL (5-FU) PLUS ENILURACIL (776C85) IN PATIENTS WITH METASTATIC COLORECTAL-CANCER - A QUALITY-OF-LIFE (QOL) EVALUATION, Annals of oncology, 9, 1998, pp. 168-168
A PHASE-I AND PHARMACOKINETIC (PK) STUDY OF ET-743, A NOVEL MINOR-GROOVE BINDER OF MARINE ORIGIN ADMINISTERED ON A DAILY X 5 SCHEDULE
Authors: HIDALGO M VILLALONACALERO MA ECKHARDT SG WEISS G CAMPBELL E KRAYNAK M BEIJNEN J JIMENO J VONHOFF D ROWINSKY E
Citation: M. Hidalgo et al., A PHASE-I AND PHARMACOKINETIC (PK) STUDY OF ET-743, A NOVEL MINOR-GROOVE BINDER OF MARINE ORIGIN ADMINISTERED ON A DAILY X 5 SCHEDULE, Annals of oncology, 9, 1998, pp. 613-613
A PHASE-I AND PHARMACOKINETIC (PK) STUDY OF THE MULTITARGETED ANTIFOLATE (MTA, LY231514) WITH FOLIC-ACID (FA)
Authors: HAMMOND L VILLALONACALERO M ECKHARDT SG SIU L HIDALGO M THORNTON D WALLING J BAKER S COLTMAN C VONHOFF D ROWINSKY E
Citation: L. Hammond et al., A PHASE-I AND PHARMACOKINETIC (PK) STUDY OF THE MULTITARGETED ANTIFOLATE (MTA, LY231514) WITH FOLIC-ACID (FA), Annals of oncology, 9, 1998, pp. 620-620
CYTOCHROME-P-450 METABOLISM OF THE REBECCAMYCIN ANALOG NSC655649
Authors: RIZZO J RENOUF J ECKHARDT SG WEITMAN S ROWINSKY E KUHN J
Citation: J. Rizzo et al., CYTOCHROME-P-450 METABOLISM OF THE REBECCAMYCIN ANALOG NSC655649, Annals of oncology, 9, 1998, pp. 231-231
A PHASE-I AND PHARMACOKINETIC (PK) STUDY OF DX-8951F, A NOVEL HEXACYCLIC CAMPTOTHECIN (CPT) ANALOG, ON A 30 MINUTE INFUSION DAILY FOR 5 DAYS EVERY 3 WEEK SCHEDULE
Authors: JOHNSON T GEYER C DEJAGER R ECKHARDT SG SMETZER L CLARK G COYLE J DRENGLER R VONHOFF D ROWINSKY E
Citation: T. Johnson et al., A PHASE-I AND PHARMACOKINETIC (PK) STUDY OF DX-8951F, A NOVEL HEXACYCLIC CAMPTOTHECIN (CPT) ANALOG, ON A 30 MINUTE INFUSION DAILY FOR 5 DAYS EVERY 3 WEEK SCHEDULE, Annals of oncology, 9, 1998, pp. 245-245
PHASE-I AND PHARMACOKINETIC (PK) STUDY OF LU79553, A NOVEL BIS-NAPHTHALAMIDE ON A DAILY X 5 SCHEDULE
Authors: VILLALONACALERO M EDER J TOPPMEYER D ALLEN L VELAGAPUDI R MYERS M AMATO A KAGENHALLET K RAZVILLAS B OCONNOR L FRAM R KUFE D VONHOFF D ROWINSKY E
Citation: M. Villalonacalero et al., PHASE-I AND PHARMACOKINETIC (PK) STUDY OF LU79553, A NOVEL BIS-NAPHTHALAMIDE ON A DAILY X 5 SCHEDULE, Annals of oncology, 9, 1998, pp. 249-249
PROLONGED ADMINISTRATION OF BAY-12-9566, AN ORAL NONPEPTIDIC BIPHENYLMATRIX - A PHASE-I AND PHARMACOLOGICAL STUDY
Authors: ROWINSKY E HAMMOND L AYLESWORTH C HUMPHREY R SMETZER L SIU L WEISS G SMITH L THURMAN A RODRIGUEZ G SORENSEN M VONHOFF D ECKHARDT SG
Citation: E. Rowinsky et al., PROLONGED ADMINISTRATION OF BAY-12-9566, AN ORAL NONPEPTIDIC BIPHENYLMATRIX - A PHASE-I AND PHARMACOLOGICAL STUDY, Annals of oncology, 9, 1998, pp. 287-287
COMPARISON OF PROLONGED AND SHORT-TERM EXPOSURE PACLITAXEL (TAXOL(R))USING THE HUMAN TUMOR CLONING ASSAY
Authors: RAYMOND E FAIVRE S IZBICKA E CLARK G ROWINSKY E HANAUSKE A VONHOFF D
Citation: E. Raymond et al., COMPARISON OF PROLONGED AND SHORT-TERM EXPOSURE PACLITAXEL (TAXOL(R))USING THE HUMAN TUMOR CLONING ASSAY, Annals of oncology, 9, 1998, pp. 351-351
PHASE-I STUDY OF CAPECITABINE IN COMBINATION WITH PACLITAXEL IN PATIENTS WITH PREVIOUSLY TREATED METASTATIC BREAST-CANCER
Authors: VILLALONACALERO M BLUM J DIAB S ELLEDGE R KHOURY P KRAYNAK M MOCZYGEMBA J KROMELIS P IMPELLIZERI K GRIFFIN T VONHOFF D ROWINSKY E
Citation: M. Villalonacalero et al., PHASE-I STUDY OF CAPECITABINE IN COMBINATION WITH PACLITAXEL IN PATIENTS WITH PREVIOUSLY TREATED METASTATIC BREAST-CANCER, Annals of oncology, 9, 1998, pp. 370-370
PHASE-I AND PHARMACOKINETIC (PK) STUDY OF THE DIARYLSULFONYLUREA LY295501 ADMINISTERED AS A SINGLE ORAL DOSE WEEKLY FOR 3 WEEKS EVERY 4 WEEKS
Authors: DIAB S BAKER SD HAMMOND L VILLALONA M ECKHARDT SG TINU C WEISS G KRAYNAK M AYLESWORTH C SMITH L RODRIGUEZ G DRENGLER R PATIL R SIU L ROTHENBERG M SMETZER L NYHART E STORNIOLO AM VONHOFF D ROWINSKY E
Citation: S. Diab et al., PHASE-I AND PHARMACOKINETIC (PK) STUDY OF THE DIARYLSULFONYLUREA LY295501 ADMINISTERED AS A SINGLE ORAL DOSE WEEKLY FOR 3 WEEKS EVERY 4 WEEKS, Annals of oncology, 9, 1998, pp. 440-440
PHASE-I AND PHARMACOKINETIC (PK) TRIAL OF SEQUENCES OF BCNU AND TEMOZOLOMIDE (TMZ) IN PATIENTS WITH SOLID NEOPLASMS
Authors: HAMMOND L ECKARDT J KUHN J RIZZO J JOHNSON T VILLALONACALERO M SMITH L DRENGLER R CAMPBELL L VONHOFF D ROWINSKY E
Citation: L. Hammond et al., PHASE-I AND PHARMACOKINETIC (PK) TRIAL OF SEQUENCES OF BCNU AND TEMOZOLOMIDE (TMZ) IN PATIENTS WITH SOLID NEOPLASMS, Annals of oncology, 9, 1998, pp. 441-441
A PHASE-I AND PHARMACOKINETIC STUDY OF ET-743, A NOVEL DNA MINOR-GROOVE BINDER OF MARINE ORIGIN, ADMINISTERED AS A 1-HOUR INFUSION DAILY X 5 DAYS
Authors: VILLALONACALERO M ECKHARDT SG WEISS G CAMPBELL E HIDALGO M KRAYNAK M BEIJNEN J JIMENO J VONHOFF D ROWINSKY E
Citation: M. Villalonacalero et al., A PHASE-I AND PHARMACOKINETIC STUDY OF ET-743, A NOVEL DNA MINOR-GROOVE BINDER OF MARINE ORIGIN, ADMINISTERED AS A 1-HOUR INFUSION DAILY X 5 DAYS, Annals of oncology, 9, 1998, pp. 453-453
A PHASE-I SAFETY AND PHARMACOKINETIC (PK) STUDY OF BCH-4556, A NOVEL L-NUCLEOSIDE ANTIMETABOLITE, ON A DAILY X 5 DAY EVERY 21-DAY SCHEDULE IN PATIENTS WITH SOLID NEOPLASMS
Authors: STEPHENSON J BAKER SD AYLESWORTH C SIU L SIMMONS C SHARMA S SMITH L PROULX L MARSOLAIS C HUNT W VONHOFF D ROWINSKY E
Citation: J. Stephenson et al., A PHASE-I SAFETY AND PHARMACOKINETIC (PK) STUDY OF BCH-4556, A NOVEL L-NUCLEOSIDE ANTIMETABOLITE, ON A DAILY X 5 DAY EVERY 21-DAY SCHEDULE IN PATIENTS WITH SOLID NEOPLASMS, Annals of oncology, 9, 1998, pp. 596-596
PHASE-I AND PHARMACOKINETIC (PK) STUDY OF THE GLYCINAMIDE RIBONUCLEOTIDE FORMYLTRANSFERASE INHIBITOR LY309887 AS A BOLUS EVERY 3 WEEKS WITHFOLIC-ACID
Authors: AYLESWORTH C BAKER SD STEPHENSON J BRITTEN C MONROE P WALLING J JOHNSON R VONHOFF D ROWINSKY E
Citation: C. Aylesworth et al., PHASE-I AND PHARMACOKINETIC (PK) STUDY OF THE GLYCINAMIDE RIBONUCLEOTIDE FORMYLTRANSFERASE INHIBITOR LY309887 AS A BOLUS EVERY 3 WEEKS WITHFOLIC-ACID, Annals of oncology, 9, 1998, pp. 610-610
A PHASE-I AND PHARMACOKINETIC (PK) STUDY OF ZD9331, A NOVEL LONG-ACTING THYMIDYLATE SYNTHETASE (TS) INHIBITOR, ON A SINGLE DOSING EVERY 3 WEEKS SCHEDULE
Authors: DIAB S BRITTEN C SMITH R ECKHARDT SG BAKER S HAMMOND L SIU L SHARMA S HIDALGO M AYLESWORTH C YOUNG R WONG L RAZVILLAS B KRAYNAK M DOUGLASS E VONHOFF D ROWINSKY E
Citation: S. Diab et al., A PHASE-I AND PHARMACOKINETIC (PK) STUDY OF ZD9331, A NOVEL LONG-ACTING THYMIDYLATE SYNTHETASE (TS) INHIBITOR, ON A SINGLE DOSING EVERY 3 WEEKS SCHEDULE, Annals of oncology, 9, 1998, pp. 611-611
A PHASE-I AND PHARMACOKINETIC (PK) STUDY OF THE MULTITARGETED ANTIFOL(MTA) LY231514 WITH FOLIC-ACID (FA)
Authors: HAMMOND L BAKER SD VILLALONACALERO M ECKHARDT SG DRENGLER R AYLESWORTH C JOHNSON T HIDALGO M RODRIGUEZ G DIAB S MONROE P THORNTON D JOHNSON R VONHOFF D ROWINSKY E
Citation: L. Hammond et al., A PHASE-I AND PHARMACOKINETIC (PK) STUDY OF THE MULTITARGETED ANTIFOL(MTA) LY231514 WITH FOLIC-ACID (FA), Annals of oncology, 9, 1998, pp. 612-612
A PHASE-I DOSE-ESCALATION STUDY OF THE MULTITARGETED ANTIFOLATE, LY231514 (MTA) IN COMBINATION WITH 5-FLUOROURACIL (5-FU) - DEPENDENCE OF TOXICITY ON SCHEDULE OF 5-FU ADMINISTRATION
Authors: JOHNSON T SCHWARTZ G MCCUNE D STEPHENSON J AYLESWORTH C HAMMOND L MONROE P THORNTON D VONHOFF D ROWINSKY E
Citation: T. Johnson et al., A PHASE-I DOSE-ESCALATION STUDY OF THE MULTITARGETED ANTIFOLATE, LY231514 (MTA) IN COMBINATION WITH 5-FLUOROURACIL (5-FU) - DEPENDENCE OF TOXICITY ON SCHEDULE OF 5-FU ADMINISTRATION, Annals of oncology, 9, 1998, pp. 613-613
PLASMA 2'-DEOXYURIDINE (DURD) AS A SURROGATE MARKER OF THYMIDYLATE SYNTHASE (TS) INHIBITION IN PATIENTS IN PHASE-I CLINICAL-TRIALS OF THE TS INHIBITOR ZD9331
Authors: MITCHELL F LYNN S REES C JUDSON I CALVERT AH RATAIN M DIAB S ROWINSKY E MAYNE K JACKMAN AL
Citation: F. Mitchell et al., PLASMA 2'-DEOXYURIDINE (DURD) AS A SURROGATE MARKER OF THYMIDYLATE SYNTHASE (TS) INHIBITION IN PATIENTS IN PHASE-I CLINICAL-TRIALS OF THE TS INHIBITOR ZD9331, Annals of oncology, 9, 1998, pp. 614-614
A PHASE-I AND PHARMACOKINETIC (PK) STUDY OF PN401 AS A RESCUE AGENT FOR ESCALATING DOSES OF 5-FLUOROURACIL (5-FU) IN PATIENTS WITH CANCER
Authors: HIDALGO M VILLALONACALERO MA BRITTEN C SIU L DRENGLER R HAMMOND L DIAB S CAMPBELL E LOUIE A ONEIL J VONHOFF D ROWINSKY E
Citation: M. Hidalgo et al., A PHASE-I AND PHARMACOKINETIC (PK) STUDY OF PN401 AS A RESCUE AGENT FOR ESCALATING DOSES OF 5-FLUOROURACIL (5-FU) IN PATIENTS WITH CANCER, Annals of oncology, 9, 1998, pp. 625-625
PHASE-I AND PHARMACOKINETIC STUDY OF THE WATER-SOLUBLE DOLASTATIN-15 ANALOG LU103793 IN PATIENTS WITH ADVANCED SOLID MALIGNANCIES
Authors: VILLALONACALERO MA BAKER SD HAMMOND L AYLESWORTH C ECKHARDT SG KRAYNAK M FRAM R FISCHKOFF S VELAGAPUDI R TOPPMEYER D RAZVILLAS B JAKIMOWICZ K VANHOFF DD ROWINSKY E
Citation: Ma. Villalonacalero et al., PHASE-I AND PHARMACOKINETIC STUDY OF THE WATER-SOLUBLE DOLASTATIN-15 ANALOG LU103793 IN PATIENTS WITH ADVANCED SOLID MALIGNANCIES, Journal of clinical oncology, 16(8), 1998, pp. 2770-2779
PREIRRADIATION PACLITAXEL IN GLIOBLASTOMA-MULTIFORME - EFFICACY, PHARMACOLOGY, AND DRUG-INTERACTIONS
Authors: FETELL MR GROSSMAN SA FISHER JD ERLANGER B ROWINSKY E STOCKEL J PIANTADOSI S
Citation: Mr. Fetell et al., PREIRRADIATION PACLITAXEL IN GLIOBLASTOMA-MULTIFORME - EFFICACY, PHARMACOLOGY, AND DRUG-INTERACTIONS, Journal of clinical oncology, 15(9), 1997, pp. 3121-3128
PHASE-I AND PHARMACOLOGICAL STUDIES OF TOPOTECAN IN PATIENTS WITH IMPAIRED HEPATIC-FUNCTION
Authors: OREILLY S ROWINSKY E SLICHENMYER W DONEHOWER RC FORASTIERE A ETTINGER D CHEN TL SARTORIUS S BOWLING K SMITH J BRUBAKER A LUBEJKO B IGNACIO V GROCHOW LB
Citation: S. Oreilly et al., PHASE-I AND PHARMACOLOGICAL STUDIES OF TOPOTECAN IN PATIENTS WITH IMPAIRED HEPATIC-FUNCTION, Journal of the National Cancer Institute, 88(12), 1996, pp. 817-824
PHASE-I FEASIBILITY AND PHARMACOLOGICAL STUDY OF WEEKLY INTRAPERITONEAL PACLITAXEL - A GYNECOLOGIC-ONCOLOGY-GROUP PILOT-STUDY
Authors: FRANCIS P ROWINSKY E SCHNEIDER J HAKES T HOSKINS W MARKMAN M
Citation: P. Francis et al., PHASE-I FEASIBILITY AND PHARMACOLOGICAL STUDY OF WEEKLY INTRAPERITONEAL PACLITAXEL - A GYNECOLOGIC-ONCOLOGY-GROUP PILOT-STUDY, Journal of clinical oncology, 13(12), 1995, pp. 2961-2967
INTRAPERITONEAL PACLITAXEL - A POSSIBLE ROLE IN THE MANAGEMENT OF OVARIAN-CANCER
Authors: MARKMAN M FRANCIS P ROWINSKY E HOSKINS W
Citation: M. Markman et al., INTRAPERITONEAL PACLITAXEL - A POSSIBLE ROLE IN THE MANAGEMENT OF OVARIAN-CANCER, Seminars in oncology, 22(3), 1995, pp. 84-87
EASTERN-COOPERATIVE-ONCOLOGY-GROUP STUDIES OF PACLITAXEL AND DOXORUBICIN IN ADVANCED BREAST-CANCER
Authors: SLEDGE GW ROBERT N SPARANO JA COGLEIGH M GOLDSTEIN LJ NEUBERG D ROWINSKY E BAUGHMAN C MCCASKILLSTEVENS W
Citation: Gw. Sledge et al., EASTERN-COOPERATIVE-ONCOLOGY-GROUP STUDIES OF PACLITAXEL AND DOXORUBICIN IN ADVANCED BREAST-CANCER, Seminars in oncology, 22(3), 1995, pp. 105-108
Risultati: 1-25 | 26-27